Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: Protocol for a Randomized Controlled Trial (CanPatch)

Pim Sermsaksasithorn, Pravit Asawanonda, Phanupong Phutrakool, Thunnicha Ondee, Pajaree Chariyavilaskul, Sunchai Payungporn, Krit Pongpirul, Nattiya Hirankarn
doi: https://doi.org/10.1101/2023.03.08.23286926

ABSTRACT

Background Existing topical psoriasis treatments are partially effective or have long-term side effects for a proportion of people with psoriasis; therefore, effective and safe treatment options are required. Cannabidiol, a cannabinoid in Cannabis sativa, reverses the etiology of psoriasis through skin receptors according to in vitro research. Cannabidiol transdermal patches may be an effective treatment for psoriasis, although the efficacy and safety data are limited.

Methods and analysis This is a randomized double-blind controlled trial comparing cannabidiol (CBD) with minimal tetrahydrocannabinol (THC) patches with placebo patches (1:1 ratio) daily applied to comparable lesions of each patient with mild to moderate plaque-type psoriasis performed in a university hospital in Thailand (n=60). The primary outcome is the local psoriasis severity index (LPSI). The local severity index of psoriasis, the itch score using the visual analog scale, and adverse events will be evaluated on day 0, 30, 60, and 90 of the study. Furthermore, on days 0 and 90 of this study, biological samples will be taken for the evaluation of the skin, gut, and mouth microbial profile of 50% of randomly selected individuals.

Conclusions This study aims to investigate the efficacy and safety of cannabidiol transdermal patches in alleviating the symptoms of psoriasis. We will also examine personal impacts on the efficacy and safety of patches, such as the microbial profile. The results of this study may highlight a novel topical treatment option that reduces suffering in patients with psoriasis.

Ethics and dissemination This study was registered with the. The protocol is being considered by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University. The results of this study will be faithfully presented through conferences or published articles.

INTRODUCTION

Psoriasis is a common chronic immune-mediated systemic disease with physical, psychological, and social burden due to its disfiguring effects and substantial comorbidities, including psoriatic arthritis, metabolic diseases, inflammatory bowel disease, cardiovascular diseases, and psychiatric disorders [1-4]. The prevalence of this disease ranges from 0.27% to 11.4% in various countries and tends to increase [5, 6].

The pathophysiology of psoriasis is multifactorial, but the essential part is immune-mediated inflammation with IL-17 and IL-23 as key players that result in uncontrolled proliferation and dysfunctional differentiation [1, 7]. Interestingly, recent studies have shown a significant difference between the human microbiota of patients with psoriasis and the normal population, with particular genera and species of skin microbiota clearly identified on the lesional skin and disproportions of the gut microbiota that influence the pathogenesis of psoriasis via the gut-skin axis [8-16].

Most patients have psoriasis vulgaris or plaque-type psoriasis with mild to moderate severity; therefore, topical therapies are the treatment of choice. However, in some individuals, conventional topical therapy options are ineffective or accompanied by adverse effects [7, 17-23]. For these reasons, novel topical therapies are warranted.

Emerging studies in recent decades have suggested that cannabidiol (CBD), a non-addictive cannabinoid of Cannabis sativa, reverses the primary pathogenesis of psoriasis through various skin receptors, including inhibiting keratinocyte proliferation, reducing inflammation, modifying Th1-Th2 balance, and inhibiting IL-17 [24-36]. However, limited clinical studies have been conducted.

Cannabidiol (CBD) and psoriasis

Cannabinoids were found to exert opposite effects on the pathogenesis of psoriasis through skin receptors, including the CB1, CB2, GPCR55, TRPV1 and PPAR γ receptors [24-29, 37]. CBD, a cannabinoid derived from Cannabis sativa that is highly effective with minimal addictive properties, inhibits keratinocyte proliferation, reduces inflammation by inhibiting the function of NF-kB and TNF-α, modifies the balance of Th1-Th2, and alters cytokines by inhibiting IL-17 and IFN-γ [24, 27, 28, 30, 37-42].

By affecting CB1, CB2, and TRP channels in cutaneous nerve fibers, mast cells, and keratinocytes, cannabinoids also reduce itching. [38, 43, 44] In clinical trials, topical use of CBD reduced itching in patients with atopic dermatitis. [45, 46]

CBD is added to a variety of skin products, including those for psoriasis. [34, 38]. Despite a small number of clinical research studies, the current findings of the transdermal use of CBD ointment in the treatment of psoriasis are encouraging, including a significant reduction in the Psoriasis Area Severity Index (PASI) score on day 90 and the LPSI score on week 12 after the application of CBD ointment. [30, 34, 47]

Cannabidiol (CBD) transdermal patch

Transdermal patches have been widely used in transdermal drug delivery systems. [48] The advantages of transdermal patches include non-invasiveness, painlessness, avoidance of first-pass metabolism, sustained medication release, and lack of gastrointestinal adverse effects [48-50]. Furthermore, transdermal patches provide better medication control and less dose variability than other transdermal drug delivery methods, such as ointments [48]. However, the lipophilic nature of cannabis makes formulation and absorption challenging for therapeutic impact, including poor skin diffusion [50-52]. Medium chain triglycerides (MCTs) have been found to be pharmaceutical carriers of lipophilic drugs [53] and used for cannabis preparation in both in vitro and in vivo studies [54-57].

Safety of Cannabidiol (CBD)

Cannabidiol accumulates in organs of high blood supply such as the heart, brain, liver, and lungs when it enters the body [50]. The serious adverse events of CBD are hepatocellular damage, pneumonia, cardiovascular disease, and decreased fertility [58, 59]. However, many of the damage mentioned and alterations in vitro cell viability occurred at doses of more than 200 mg/kg/day [60]. Appetite loss, diarrhea, drowsiness, and sedation are other side effects [58, 59]. Chronic CBD causes the accumulation of CBD in adipose tissue, resulting in weeks of lethargy and sedation [50]. With the topical application of CBD, previous studies have not reported serious adverse events. Minorities experience minor adverse events, including erythema, skin irritation or pain, changes in hair or skin color, somnolence, and diarrhea [31, 32, 61-66].

Gut, skin, and oral microbiota in psoriasis

Most of the research indicated significant changes in the microbial profile in patients with psoriasis. Substantial changes in overall biodiversity, decreased α-diversity, and increased β-diversity of the skin microbiota were discovered in psoriatic skin compared to healthy and non-lesional skin [8, 12, 67, 68]. The discovery of the hypothesis of the gut-skin axis stated that gut microbial dysbiosis leads to increased inflammatory cytokines and lessened tight junction integrity that allows blood and skin access to bacterial components and metabolite products [8, 11, 13, 15, 69, 70]. Subsequently, the studies revealed a reduction in the overall diversity of intestinal microbials and significant changes in β-diversity of the intestinal microbiome diversity in patients with psoriasis [15, 16, 68, 70, 71].

Some taxonomy of the microbiota distinguishes psoriasis from normal presentation. Compared to normal skin, the combined relative abundance of Streptococcus spp., Staphylococcus spp. and Corynebacterium spp. increases in psoriatic skin, while the abundance of Staphylococcus epidermidis, Cutibacterium acnes, and Cutibacterium granulosum decreases [11, 12, 72]. The Firmicutes to Bacteroidetes ratio (F/B ratio), two main phyla of the human gut microbiota, increases in patients with psoriasis, directly correlated with PASI scores and psoriasis comorbidities [8, 13-16]. Augmentation of Ruminococcus gnavus increased and underrepresentation of Faecalibacterium prausnitzii and Akkermansia muciniphila were also found in the intestinal microbiota of patients with psoriasis [8-10, 13, 15, 16, 70, 73].

For the oral microbiome, the interaction with psoriasis pathogenesis is not well established. Compared to healthy controls, patients with psoriasis are 1.55 times more likely to develop periodontal disease, a shared mechanism involving elevated Th-17 cells and IL-17 [74]. The microbiome was distinct in the saliva of periodontal disease [75-77]. No significance was found in α- or β-diversity of the oral microbiome of patients with psoriasis compared to normal people, although 18 species did [71].

OBJECTIVES AND HYPOTHESES

Given the findings of a brief review of the literature showing promising therapeutic effects of CBD on psoriasis, we hypothesized that CBD with minimal transdermal patches of THC would be an effective and safe treatment option for psoriasis. Therefore, the main objective of this trial is to compare the efficacy of alleviating CBD psoriasis symptoms with minimal transdermal THC patches with placebo patches among patients with mild to moderate plaque-type psoriasis. Secondary objectives are to (1) report adverse events of CBD with minimal THC transdermal patches in patients with psoriasis (2) explore the microbial alteration of the gut, skin, and oral microbiome in patients with psoriasis who receive CBD with minimal THC transdermal patches and the relationship between the microbial profile and the clinical presentation of those patients.

MATERIAL AND METHODS

Study design

This is a randomized, double-blind, controlled study. This study is being approved by the Chulalongkorn University Faculty of Medicine Institutional Review Board (number XX) and registered with the Thai Clinical Trials Registry (TCTR No. 20220518004).

Participants

Participants will be recruited through direct encounter and telephone contact. The participants will be from the Division of Dermatology of King Chulalongkorn Memorial Hospital’s database. Furthermore, the online poster will be advertised (e.g., on Facebook). Participants in this trial will be selected based on medical history, medical records, and physical examination by physicians to verify if they meet eligibility criteria and consent forms in accordance with the research ethics requirements outlined in the Declaration of Helsinki. Inclusion and exclusion criteria are shown in Table 1.

View this table:
Table 1.

Inclusion and exclusion criteria.

Study medication

Intervention patches (P patches) will include 1.0 ± 0.1 mg of CBD in an MCT solvent on 2.0 ± 0.2 g of yellow adhesive layer covered with aluminum foil whereas placebo control patches (C patches) will be 2.0 g of yellow adhesive layer covered with aluminum foil.

Procedures

All participants who meet the eligibility criteria and provide their written consent are invited to respond to the baseline demographic and clinical characteristics. For each participant, two similar psoriasis lesions are selected and then randomly assigned to the intervention plaque or the control plaque in a 1:1 ratio. An overview of the progress of the current trial is shown in the consolidated standards of reporting trials diagram (Figure 1). The study and control participants are instructed to apply a P or C patch, respectively, on a selected plaque of psoriasis every day for 90 days and at least 6 hours a day.

Figure 1.
Figure 1. CONSORT flow diagram

flowchart of phases of Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: A Randomized Controlled Trial (CanPatch)

Adherence

Face-to-face reminder sessions are conducted at initial product dispensing and three subsequent visits. This session reviews the application of transdermal patches, including scheduling, storage, and missing dosage solutions. At each follow-up appointment, unused patches and used patches’ packages are tallied and documented.

Randomization

Two similar psoriasis lesions of each patient are randomly assigned to the intervention group or control group by block randomization with a ratio 1: 1 with blocks of 4 by STATA version 15.0 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC.).

Blinding

After double-blind randomization, individuals not involved in the study translate the randomization code into instructions on which patches should be used on which lesion. They place the instructions in sealed envelopes that are then delivered to patients randomly by a physician. Each lesion is instructed in the same type of patch every day. The front of an opaque sealed envelope is the study ID and the date the envelope will be opened. Therefore, patients and physicians are blinded. Allocation concealment is ensured, as the service will not release the randomization code until data collection has been completed. A code might be broken in extraordinary cases where knowledge of the actual therapy is vital for future patient care.

Trial sites

Division of Dermatology, Department of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.

Biological sample collection for genetic analysis

Biological sample collection includes 1 ml of saliva and a spoon of feces collected by participants in separate containers prepared by researchers and skin samples from three regions, two lesional skin samples, and one sample of nonlesional skin collected by skin taping by physicians. The five containers per individual containing nucleic acid preservation buffer will be transported to the laboratory in 30 minutes at room temperature or as soon as possible at 4 degrees Celsius. Upon arrival at the laboratory of the Faculty of Medicine, Chulalongkorn University, the sample will be extracted by Quick-DNA™ H M W MagBead Kit (cat. no. D6060, Zymo Research) and then amplified by the PCR method. The PCR amplification products will be purified by AMPure XP (Beckman Coulter) and the quantity will be measured by NanoPhotometer® C40 (Implen, USA). After that, DNA will be combined with the solution for the Ligation Sequencing Kit (LSK-109, Oxford Nanopore Technologies) to perform DNA sequencing using the Nanopore MinION sequencing system. All samples will be recorded and barcoded with a unique storage ID.

Data collection and management

Data collection in this study is based on personal characteristics, clinical evaluations, and self-reported measures. Baseline demographic and clinical characteristics include age (years), sex, weight, body mass index (BMI), familial history of psoriasis, duration of psoriasis, comorbidities (diabetes mellitus, hypertension, dyslipidemia, obesity, metabolic syndrome, cardiovascular disease, psoriatic arthritis, inflammatory bowel disease, psychiatric disorders, among others) and concurrent therapies for systemic psoriasis. The local psoriasis severity index (LPSI), self-reported itching on the visual analog scale, reported adverse events, and microbial profile are collected at the time points below.

All investigators will have access to the final trial data set. All documents will be safely stored in the Skin Unit Research Facilities for Academic and Clinical Excellence (SURFACE), Division of Dermatology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, for ten years. No identifiable data will be recorded and all documents will be recorded with the research identification number.

Outcome measures

Evaluations are collected at four time points: 0th, 30th, 60th and 90th day of the study. Fifty percent of the participants are chosen at random to have their saliva, feces, and skin samples collected if they consent to the storage and future testing of biological materials. An overview of all the assessment points and results is shown in Table 2.

View this table:
Table 2.

SPIRIT Schedule for enrollment, interventions, and assessments.

Local psoriasis severity index (LPSI)

Each lesion will be assessed with a modified psoriasis area severity index called the local psoriasis severity index (LPSI). The LPSI is the sum of the following symptoms evaluated by the physician: erythema (redness), induration (thickness) and desquamation (scaling infiltration). Each score was classified as follows: 0 = no symptoms, 1 = slight symptoms, 2 = moderate symptoms, 3 = marked symptoms, 4 = very marked symptoms [78]. P.A., a dermatology professor, conducts all LPSI evaluations for this study.

Secondary outcome measure

The itch score by the visual analog scale

The visual analog scale consists of a line 10 cm long, with verbal anchors at either end. The patient places a mark on the line corresponding to the patient’s intensity rating. VAS is one of the most commonly used methods for assessing the severity of pruritus, as it provides an easy, rapid and valid estimate of the itch [79-81]. Participants will be asked to indicate the point within three minutes of this study.

The alpha-diversity, beta-diversity, and relative abundance of microbiota

Biological samples, including saliva, feces, and skin, will be analyzed for microbial alteration in the form of microbial diversity. The diversity of microbes will be defined as the proportion and abundance distribution of different types of organism. The abundance distribution includes alpha diversity, which is an abundance of different bacterial taxa in a single sample, and beta diversity, which is microbial diversity in different samples. Relative abundance is the ratio of the absolute abundance of a taxon to the total absolute abundance of all taxa in a unit volume of an ecosystem. [8, 82, 83]

Reporting of adverse events

Participants are encouraged to contact research staff if they have concerns about mental or physical health decline. Upon the occurrence of an adverse event, the patient would receive treatment for the adverse event at King Chulalongkorn Memorial Hospital for free.

Discontinuation and withdrawal

Patients who experience major adverse effects after enrolling in the study, participate less than 80% of the research period, or are unwilling to continue participating in the trial will be excluded. However, the data already collected and the reason for the cessation of study participation may be included in the final report.

STATISTICAL ANALYSIS

Sample size calculation

This study compares the mean LPSI score of transdermal CBD and placebo use. With the 80% power, α = 0.05, effect size 0.58, and allocation ratio 1:1, the determined sample size per group is 48 individuals. However, there is a potential for around 20% of the individuals to drop out of the study. The researchers determine that the total sample size is 60 individuals.

Statistical method

Statistical analysis will be performed using STATA version 15.0 (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC.). Categorical data will be expressed as a number and depending on which is more appropriate, continuous data will be reported as mean +/- standard deviation or median +/- interquartile range. Qualitative variables will be presented in a table and then analyzed by the Chi-square test or Fisher’s exact test. The paired T-test or the unpaired T-test will be applied for quantitative data with normal distribution. The Wilcoxon signed ranks test or Mann-Whitney U test will be used for the quantitative data, which is not present with normal distribution.

Sequencing and Microbiome data analysis

The taxonomic classification will be assigned for the V3/V4 16S region. All taxonomic classifications will be implemented within QIIME2. Bacterial diversity is determined by alpha diversity and beta diversity, which will be calculated by the QIIME 2 pipeline. Alpha diversity will be analyzed using Shannon’s diversity and Simpson’s diversity. Beta diversity will be analyzed by Bray-Curtis dissimilarity.

TRIAL STATUS AND TIMELINE

The research will be advertised from April 2023 to May 2023. Subsequently, subject recruitment will occur from May 2023 to June 2023. The duration of the intervention will be between July 2023 and September 2023. Data analysis will be conducted from September 2023 to December 2023. The presentation of the data and the preparation of the manuscript will be completed by January 2024.

DISCUSSION

This study will be the first randomized controlled study to assess the efficacy and safety of CBD-containing transdermal patches with minimal THC in patients with mild to moderate plaque-type psoriasis. It will also be the first to investigate the correlation of the baseline and alteration of the microbial profile and the efficacy and safety of CBD with minimal THC patches, which can help with customized patches, in addition to age, sex, BMI, and genetic variables. If the intervention shows significant positive results, the promise of minimal THC transdermal CBD patches as an alternative topical therapy option for psoriasis sufferers will be emphasized, and additional studies on a larger scale may be conducted on this issue. Further research could examine (i) the efficacy and cost-effectiveness compared to the standard of care, (ii) barriers to implementation (e.g. social stigma, cost of administration, and legalization policies)

The strengths of this study include (i) a double-blind randomized design, (ii) a review of the aspects of the patients and physicians of the psoriasis symptoms, (iv) transdermal patches that could better control the amount of CBD than the previous form of transdermal CBD administration, and (v) investigation of personalized factors that include the microbial profile and demographic and clinical characteristics. However, this study also has several limitations including (i) recruiting and providing intervention at a single site and in an academic medical center setting that could limit generalizability and (ii) the subjective nature of the itch score, which includes individual variation. The study results will be released to the participating physicians, patients, and the general medical community. For reproducible research, we will transfer a collection of entirely anonymized data to a suitable data archive for sharing purposes. Any protocol amendment will be approved by the Institutional Review Board of Chulalongkorn University and the Thai Clinical Trials Registry prior to implementation.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Authors’ contributions

PS, KP, PA, PP, SV, TO, and SC conceived of the study and initiated the study design. PS wrote original draft. PS, KP, PA, and PP review and edit the draft. KP and PA supervised. PP provided statistical expertise in clinical trial design and primary statistical analysis. All authors contributed to the refinement of the study protocol and approved the final manuscript.

Supporting Information

Supplementary 1. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents.

Acknowledgements

None.

Footnotes

  • Funding: The study has received financial support from the Thai Traditional Medical Knowledge Fund. The funder has no role in the design, analysis, or writing of the study.

  • Competing interests: None.

  • Data availability: All data relevant to the study are included in the article and supplementary documents.

References

  1. 1.↵
    Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet (London, England). 2021;397(10281):1301–15. Epub 2021/04/05. doi: 10.1016/s0140-6736(20)32549-6. PubMed PMID: 33812489.
    OpenUrlCrossRefPubMed
  2. 2.
    Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV. 2017;31(2):205–12. Epub 2016/08/31. doi: 10.1111/jdv.13854. PubMed PMID: 27573025.
    OpenUrlCrossRefPubMed
  3. 3.
    Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatologic therapy. 2010;23(2):114–8. Epub 2010/04/27. doi: 10.1111/j.1529-8019.2010.01304.x. PubMed PMID: 20415817.
    OpenUrlCrossRefPubMed
  4. 4.↵
    Oliveira Mde F, Rocha Bde O, Duarte GV. Psoriasis: classical and emerging comorbidities. Anais brasileiros de dermatologia. 2015;90(1):9–20. Epub 2015/02/13. doi: 10.1590/abd1806-4841.20153038. PubMed PMID: 25672294; PubMed Central PMCID: PMCPMC4323693.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Iskandar IYK, Parisi R, Griffiths CEM, Ashcroft DM. Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender. The British journal of dermatology. 2021;184(2):243–58. Epub 2020/05/03. doi: 10.1111/bjd.19169. PubMed PMID: 32358790.
    OpenUrlCrossRefPubMed
  6. 6.↵
    Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ (Clinical research ed). 2020;369:m1590. Epub 2020/05/30. doi: 10.1136/bmj.m1590. PubMed PMID: 32467098; PubMed Central PMCID: PMCPMC7254147.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. International journal of molecular sciences. 2019;20(6). Epub 2019/03/27. doi: 10.3390/ijms20061475. PubMed PMID: 30909615; PubMed Central PMCID: PMCPMC6471628.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Olejniczak-Staruch I, Ciążyńska M, Sobolewska-Sztychny D, Narbutt J, Skibińska M, Lesiak A. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. International journal of molecular sciences. 2021;22(8). Epub 2021/05/01. doi: 10.3390/ijms22083998. PubMed PMID: 33924414; PubMed Central PMCID: PMCPMC8069836.
    OpenUrlCrossRefPubMed
  9. 9.
    Chen G, Chen ZM, Fan XY, Jin YL, Li X, Wu SR, et al. Gut-Brain-Skin Axis in Psoriasis: A Review. Dermatology and therapy. 2021;11(1):25–38. Epub 2020/11/19. doi: 10.1007/s13555-020-00466-9. PubMed PMID: 33206326; PubMed Central PMCID: PMCPMC7859123.
    OpenUrlCrossRefPubMed
  10. 10.↵
    Chen L, Li J, Zhu W, Kuang Y, Liu T, Zhang W, et al. Skin and Gut Microbiome in Psoriasis: Gaining Insight Into the Pathophysiology of It and Finding Novel Therapeutic Strategies. Frontiers in microbiology. 2020;11:589726. Epub 2021/01/02. doi: 10.3389/fmicb.2020.589726. PubMed PMID: 33384669; PubMed Central PMCID: PMCPMC7769758.
    OpenUrlCrossRefPubMed
  11. 11.↵
    De Francesco MA, Caruso A. The Gut Microbiome in Psoriasis and Crohn’s Disease: Is Its Perturbation a Common Denominator for Their Pathogenesis? Vaccines. 2022;10(2). Epub 2022/02/27. doi: 10.3390/vaccines10020244. PubMed PMID: 35214702; PubMed Central PMCID: PMCPMC8877283.
    OpenUrlCrossRefPubMed
  12. 12.↵
    Ferček I, Lugović-Mihić L, Tambić-Andrašević A, Ćesić D, Grginić AG, Bešlić I, et al. Features of the Skin Microbiota in Common Inflammatory Skin Diseases. Life (Basel, Switzerland). 2021;11(9). Epub 2021/09/29. doi: 10.3390/life11090962. PubMed PMID: 34575111; PubMed Central PMCID: PMCPMC8468136.
    OpenUrlCrossRefPubMed
  13. 13.↵
    Sikora M, Stec A, Chrabaszcz M, Knot A, Waskiel-Burnat A, Rakowska A, et al. Gut Microbiome in Psoriasis: An Updated Review. Pathogens (Basel, Switzerland). 2020;9(6). Epub 2020/06/18. doi: 10.3390/pathogens9060463. PubMed PMID: 32545459; PubMed Central PMCID: PMCPMC7350295.
    OpenUrlCrossRefPubMed
  14. 14.
    Kierasińska M, Donskow-Łysoniewska K. Both the microbiome and the macrobiome can influence immune responsiveness in psoriasis. Central-European journal of immunology. 2021;46(4):502–8. Epub 2022/02/08. doi: 10.5114/ceji.2021.110314. PubMed PMID: 35125950; PubMed Central PMCID: PMCPMC8808298.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Polak K, Bergler-Czop B, Szczepanek M, Wojciechowska K, Frątczak A, Kiss N. Psoriasis and Gut Microbiome-Current State of Art. International journal of molecular sciences. 2021;22(9). Epub 2021/05/01. doi: 10.3390/ijms22094529. PubMed PMID: 33926088; PubMed Central PMCID: PMCPMC8123672.
    OpenUrlCrossRefPubMed
  16. 16.↵
    Colucci R, Moretti S. Implication of Human Bacterial Gut Microbiota on Immune-Mediated and Autoimmune Dermatological Diseases and Their Comorbidities: A Narrative Review. Dermatology and therapy. 2021;11(2):363–84. Epub 2021/01/29. doi: 10.1007/s13555-021-00485-0. PubMed PMID: 33507493; PubMed Central PMCID: PMCPMC8018919.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Le Roux E, Frow H. Diagnosis and management of mild to moderate psoriasis. Prescriber. 2020;31(7-8):9–17. doi: https://doi.org/10.1002/psb.1855.
    OpenUrl
  18. 18.
    Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. Jama. 2020;323(19):1945–60. Epub 2020/05/20. doi: 10.1001/jama.2020.4006. PubMed PMID: 32427307.
    OpenUrlCrossRefPubMed
  19. 19.
    Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? Journal of the American Academy of Dermatology. 2000;43(2 Pt 1):281–5. Epub 2000/07/25. doi: 10.1067/mjd.2000.106374. PubMed PMID: 10906652.
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.
    Papp KA, Gniadecki R, Beecker J, Dutz J, Gooderham MJ, Hong CH, et al. Psoriasis Prevalence and Severity by Expert Elicitation. Dermatology and therapy. 2021;11(3):1053–64. Epub 2021/04/23. doi: 10.1007/s13555-021-00518-8. PubMed PMID: 33886086; PubMed Central PMCID: PMCPMC8163919.
    OpenUrlCrossRefPubMed
  21. 21.
    Chiricozzi A, Pimpinelli N, Ricceri F, Bagnoni G, Bartoli L, Bellini M, et al. Treatment of psoriasis with topical agents: Recommendations from a Tuscany Consensus. Dermatologic therapy. 2017;30(6). Epub 2017/09/25. doi: 10.1111/dth.12549. PubMed PMID: 28940579.
    OpenUrlCrossRefPubMed
  22. 22.
    Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Canadian family physician Medecin de famille canadien. 2017;63(4):278–85. Epub 2017/04/14. PubMed PMID: 28404701; PubMed Central PMCID: PMCPMC5389757.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    Kessler TR. Treating patients with moderate-to-severe psoriasis vulgaris. JAAPA : official journal of the American Academy of Physician Assistants. 2022;35(3):28–35. Epub 2022/02/05. doi: 10.1097/01.JAA.0000819580.10133.b1. PubMed PMID: 35120363.
    OpenUrlCrossRefPubMed
  24. 24.↵
    Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, et al. Therapeutic Potential of Cannabidiol (CBD) for Skin Health and Disorders. Clinical, cosmetic and investigational dermatology. 2020;13:927–42. Epub 2020/12/19. doi: 10.2147/ccid.S286411. PubMed PMID: 33335413; PubMed Central PMCID: PMCPMC7736837.
    OpenUrlCrossRefPubMed
  25. 25.
    Río CD, Millán E, García V, Appendino G, DeMesa J, Muñoz E. The endocannabinoid system of the skin. A potential approach for the treatment of skin disorders. Biochemical pharmacology. 2018;157:122–33. Epub 2018/08/24. doi: 10.1016/j.bcp.2018.08.022. PubMed PMID: 30138623.
    OpenUrlCrossRefPubMed
  26. 26.
    Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. Journal of dermatological science. 2007;45(2):87–92. Epub 2006/12/13. doi: 10.1016/j.jdermsci.2006.10.009. PubMed PMID: 17157480.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Ramot Y, Sugawara K, Zákány N, Tóth BI, Bíró T, Paus R. A novel control of human keratin expression: cannabinoid receptor 1-mediated signaling down-regulates the expression of keratins K6 and K16 in human keratinocytes in vitro and in situ. PeerJ. 2013;1:e40. Epub 2013/05/03. doi: 10.7717/peerj.40. PubMed PMID: 23638377; PubMed Central PMCID: PMCPMC3628749.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Norooznezhad AH, Norooznezhad F. Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. Medical hypotheses. 2017;99:15–8. Epub 2017/01/24. doi: 10.1016/j.mehy.2016.12.003. PubMed PMID: 28110689.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future medicinal chemistry. 2009;1(7):1333–49. Epub 2010/03/02. doi: 10.4155/fmc.09.93. PubMed PMID: 20191092; PubMed Central PMCID: PMCPMC2828614.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    Palmieri B, Laurino C, Vadalà M. A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. La Clinica terapeutica. 2019;170(2):e93–e9. Epub 2019/04/18. doi: 10.7417/ct.2019.2116. PubMed PMID: 30993303.
    OpenUrlCrossRefPubMed
  31. 31.↵
    Tijani AO, Thakur D, Mishra D, Frempong D, Chukwunyere UI, Puri A. Delivering therapeutic cannabinoids via skin: Current state and future perspectives. Journal of controlled release : official journal of the Controlled Release Society. 2021;334:427–51. Epub 2021/05/09. doi: 10.1016/j.jconrel.2021.05.005. PubMed PMID: 33964365.
    OpenUrlCrossRefPubMed
  32. 32.↵
    Mahmood F, Lim MM, Kirchhof MG. A Survey of Topical Cannabis Use in Canada. Journal of cutaneous medicine and surgery. 2022;26(2):156–61. Epub 2021/11/21. doi: 10.1177/12034754211059025. PubMed PMID: 34798780.
    OpenUrlCrossRefPubMed
  33. 33.
    Yeroushalmi S, Nelson K, Sparks A, Friedman A. Perceptions and recommendation behaviors of dermatologists for medical cannabis: A pilot survey. Complementary therapies in medicine. 2020;55:102552. Epub 2020/11/22. doi: 10.1016/j.ctim.2020.102552. PubMed PMID: 33220620.
    OpenUrlCrossRefPubMed
  34. 34.↵
    Martins AM, Gomes AL, Vilas Boas I, Marto J, Ribeiro HM. Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review. Pharmaceuticals (Basel, Switzerland). 2022;15(2). Epub 2022/02/27. doi: 10.3390/ph15020210. PubMed PMID: 35215320; PubMed Central PMCID: PMCPMC8878527.
    OpenUrlCrossRefPubMed
  35. 35.
    Tammaro A, Magri F, Chello C, Giordano D, Parisella FR, De Marco G, et al. A successful topical treatment for cutaneous inflammatory diseases:an additional or alternative therapy to topical steroids. European annals of allergy and clinical immunology. 2019;51(3):129–30. Epub 2019/05/14. doi: 10.23822/EurAnnACI.1764-1489.79. PubMed PMID: 31081604.
    OpenUrlCrossRefPubMed
  36. 36.↵
    Yeroushalmi S, Nemirovsky D, Mamlouk M, Feldman D, Nelson K, Sparks A, et al. Consumer Perspectives on and Utilization of Medical Cannabis to Treat Dermatologic Conditions. Journal of drugs in dermatology : JDD. 2022;21(1):31–6. Epub 2022/01/11. doi: 10.36849/jdd.2022.6540. PubMed PMID: 35005866.
    OpenUrlCrossRefPubMed
  37. 37.↵
    Sheriff T, Lin MJ, Dubin D, Khorasani H. The potential role of cannabinoids in dermatology. The Journal of dermatological treatment. 2020;31(8):839–45. Epub 2019/10/11. doi: 10.1080/09546634.2019.1675854. PubMed PMID: 31599175.
    OpenUrlCrossRefPubMed
  38. 38.↵
    Jhawar N, Schoenberg E, Wang JV, Saedi N. The growing trend of cannabidiol in skincare products. Clinics in dermatology. 2019;37(3):279–81. Epub 2019/06/11. doi: 10.1016/j.clindermatol.2018.11.002. PubMed PMID: 31178109.
    OpenUrlCrossRefPubMed
  39. 39.
    Martinelli G, Magnavacca A, Fumagalli M, Dell□Agli M, Piazza S, Sangiovanni E. Cannabis sativa and Skin Health: Dissecting the Role of Phytocannabinoids. Planta medica. 2022;88(7):492–506. Epub 2021/04/15. doi: 10.1055/a-1420-5780. PubMed PMID: 33851375.
    OpenUrlCrossRefPubMed
  40. 40.
    Tóth KF, Ádám D, Bíró T, Oláh A. Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System. Molecules (Basel, Switzerland). 2019;24(5). Epub 2019/03/09. doi: 10.3390/molecules24050918. PubMed PMID: 30845666; PubMed Central PMCID: PMCPMC6429381.
    OpenUrlCrossRefPubMed
  41. 41.
    Osafo N, Yeboah OK, Antwi AO. Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. Molecular biology reports. 2021;48(4):3665–80. Epub 2021/04/29. doi: 10.1007/s11033-021-06366-1. PubMed PMID: 33909195.
    OpenUrlCrossRefPubMed
  42. 42.↵
    Namazi MR. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition. Journal of the European Academy of Dermatology and Venereology : JEADV. 2005;19(3):319–22. Epub 2005/04/29. doi: 10.1111/j.1468-3083.2004.01184.x. PubMed PMID: 15857457.
    OpenUrlCrossRefPubMed
  43. 43.↵
    Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M. Cannabinoids for the treatment of chronic pruritus: A review. Journal of the American Academy of Dermatology. 2020;82(5):1205–12. Epub 2020/01/29. doi: 10.1016/j.jaad.2020.01.036. PubMed PMID: 31987788.
    OpenUrlCrossRefPubMed
  44. 44.↵
    Makhakhe L. Topical cannabidiol (CBD) in skin pathology - A comprehensive review and prospects for new therapeutic opportunities. South African family practice : official journal of the South African Academy of Family Practice/Primary Care. 2022;64(1):e1–e4. Epub 2022/06/14. doi: 10.4102/safp.v64i1.5493. PubMed PMID: 35695447; PubMed Central PMCID: PMCPMC9210160.
    OpenUrlCrossRefPubMed
  45. 45.↵
    Maghfour J, Rietcheck HR, Rundle CW, Runion TM, Jafri ZA, Dercon S, et al. An Observational Study of the Application of a Topical Cannabinoid Gel on Sensitive Dry Skin. Journal of drugs in dermatology : JDD. 2020;19(12):1204–8. Epub 2020/12/22. doi: 10.36849/jdd.2020.5464. PubMed PMID: 33346512.
    OpenUrlCrossRefPubMed
  46. 46.↵
    Maghfour J, Rundle CW, Rietcheck HR, Dercon S, Lio P, Mamo A, et al. Assessing the effects of topical cannabidiol in patients with atopic dermatitis. Dermatology online journal. 2021;27(2). Epub 2021/04/06. PubMed PMID: 33818989.
    OpenUrlPubMed
  47. 47.↵
    Puaratanaarunkon T, Sittisaksomjai S, Sivapornpan N, Pongcharoen P, Chakkavittumrong P, Ingkaninan K, et al. Topical cannabidiol-based treatment for psoriasis: A dual-centre randomized placebo-controlled study. Journal of the European Academy of Dermatology and Venereology : JEADV. 2022;36(9):e718–e20. Epub 2022/05/11. doi: 10.1111/jdv.18215. PubMed PMID: 35536599.
    OpenUrlCrossRefPubMed
  48. 48.↵
    Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and pharmacology. British journal of pharmacology. 2015;172(9):2179–209. Epub 2015/01/07. doi: 10.1111/bph.13059. PubMed PMID: 25560046; PubMed Central PMCID: PMCPMC4403087.
    OpenUrlCrossRefPubMed
  49. 49.
    Paudel KS, Milewski M, Swadley CL, Brogden NK, Ghosh P, Stinchcomb AL. Challenges and opportunities in dermal/transdermal delivery. Therapeutic delivery. 2010;1(1):109–31. Epub 2010/12/07. doi: 10.4155/tde.10.16. PubMed PMID: 21132122; PubMed Central PMCID: PMCPMC2995530.
    OpenUrlCrossRefPubMed
  50. 50.↵
    Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. British journal of clinical pharmacology. 2018;84(11):2477–82. Epub 2018/07/13. doi: 10.1111/bcp.13710. PubMed PMID: 30001569; PubMed Central PMCID: PMCPMC6177698.
    OpenUrlCrossRefPubMed
  51. 51.
    Junaid MSA, Tijani AO, Puri A, Banga AK. In vitro percutaneous absorption studies of cannabidiol using human skin: Exploring the effect of drug concentration, chemical enhancers, and essential oils. International journal of pharmaceutics. 2022;616:121540. Epub 2022/02/07. doi: 10.1016/j.ijpharm.2022.121540. PubMed PMID: 35124116.
    OpenUrlCrossRefPubMed
  52. 52.↵
    Tanner, Marks R. Delivering drugs by the transdermal route: review and comment. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI). 2008;14(3):249–60. Epub 2009/01/23. doi: 10.1111/j.1600-0846.2008.00316.x. PubMed PMID: 19159369.
    OpenUrlCrossRefPubMed
  53. 53.↵
    Ramella A, Roda G, Pavlovic R, Cas MD, Casagni E, Mosconi G, et al. Impact of Lipid Sources on Quality Traits of Medical Cannabis-Based Oil Preparations. Molecules (Basel, Switzerland). 2020;25(13). Epub 2020/07/08. doi: 10.3390/molecules25132986. PubMed PMID: 32629796; PubMed Central PMCID: PMCPMC7412533.
    OpenUrlCrossRefPubMed
  54. 54.↵
    Stolar O, Hazan A, Vissoker RE, Kishk IA, Barchel D, Lezinger M, et al. Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: An interim analysis of biochemical safety. Frontiers in pharmacology. 2022;13:977484. Epub 2022/10/18. doi: 10.3389/fphar.2022.977484. PubMed PMID: 36249785; PubMed Central PMCID: PMCPMC9559854.
    OpenUrlCrossRefPubMed
  55. 55.
    Dahlgren MK, Lambros AM, Smith RT, Sagar KA, El-Abboud C, Gruber SA. Clinical and cognitive improvement following full-spectrum, high-cannabidiol treatment for anxiety: open-label data from a two-stage, phase 2 clinical trial. Communications medicine. 2022;2(1):139. Epub 2022/11/10. doi: 10.1038/s43856-022-00202-8. PubMed PMID: 36352103; PubMed Central PMCID: PMCPMC9628346.
    OpenUrlCrossRefPubMed
  56. 56.
    Tonoyan L, Babu D, Reiz B, Le T, Siraki AG. Heating of consumer cannabis oils can lead to free radical initiated degradation, causing CBD and THC depletion. Free radical biology & medicine. 2022;192:77–83. Epub 2022/09/17. doi: 10.1016/j.freeradbiomed.2022.09.005. PubMed PMID: 36113706.
    OpenUrlCrossRefPubMed
  57. 57.↵
    Feng W, Qin C, Cipolla E, Lee JB, Zgair A, Chu Y, et al. Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulation of Cannabidiol Facilitates Micellar Solubilization In Vitro, but In Vivo Performance Remains Superior with Pure Sesame Oil Vehicle. Pharmaceutics. 2021;13(9). Epub 2021/09/29. doi: 10.3390/pharmaceutics13091349. PubMed PMID: 34575426; PubMed Central PMCID: PMCPMC8472830.
    OpenUrlCrossRefPubMed
  58. 58.↵
    Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2020;45(11):1799–806. Epub 2020/04/09. doi: 10.1038/s41386-020-0667-2. PubMed PMID: 32268347; PubMed Central PMCID: PMCPMC7608221.
    OpenUrlCrossRefPubMed
  59. 59.↵
    Meissner H, Cascella M. Cannabidiol (CBD). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC.; 2022.
  60. 60.↵
    Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and Toxicity. Current neuropharmacology. 2019;17(10):974–89. Epub 2019/06/05. doi: 10.2174/1570159x17666190603171901. PubMed PMID: 31161980; PubMed Central PMCID: PMCPMC7052834.
    OpenUrlCrossRefPubMed
  61. 61.↵
    Maghfour J, Rietcheck H, Szeto MD, Rundle CW, Sivesind TE, Dellavalle RP, et al. Tolerability profile of topical cannabidiol and palmitoylethanolamide: a compilation of single-centre randomized evaluator-blinded clinical and in□vitro studies in normal skin. Clinical and experimental dermatology. 2021;46(8):1518–29. Epub 2021/05/23. doi: 10.1111/ced.14749. PubMed PMID: 34022073.
    OpenUrlCrossRefPubMed
  62. 62.
    Xu DH, Cullen BD, Tang M, Fang Y. The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. Current pharmaceutical biotechnology. 2020;21(5):390–402. Epub 2019/12/04. doi: 10.2174/1389201020666191202111534. PubMed PMID: 31793418.
    OpenUrlCrossRefPubMed
  63. 63.
    Maida V, Shi RB, Fazzari FGT, Zomparelli L. Topical cannabis-based medicines - A novel paradigm and treatment for non-uremic calciphylaxis leg ulcers: An open label trial. International wound journal. 2020;17(5):1508–16. Epub 2020/09/03. doi: 10.1111/iwj.13484. PubMed PMID: 32875692; PubMed Central PMCID: PMCPMC7540661.
    OpenUrlCrossRefPubMed
  64. 64.
    Yin HY, Hadjokas N, Mirchia K, Swan R, Alpert S. Commercial Cannabinoid Oil-Induced Stevens-Johnson Syndrome. Case reports in ophthalmological medicine. 2020;2020:6760272. Epub 2020/03/10. doi: 10.1155/2020/6760272. PubMed PMID: 32148986; PubMed Central PMCID: PMCPMC7053463.
    OpenUrlCrossRefPubMed
  65. 65.
    Scheffer IE, Hulihan J, Messenheimer J, Ali S, Keenan N, Griesser J, et al. Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies: A Nonrandomized Controlled Trial. JAMA network open. 2021;4(9):e2123930. Epub 2021/09/04. doi: 10.1001/jamanetworkopen.2021.23930. PubMed PMID: 34477852; PubMed Central PMCID: PMCPMC8417764.
    OpenUrlCrossRefPubMed
  66. 66.↵
    Heussler H, Cohen J, Silove N, Tich N, Bonn-Miller MO, Du W, et al. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome. Journal of neurodevelopmental disorders. 2019;11(1):16. Epub 2019/08/03. doi: 10.1186/s11689-019-9277-x. PubMed PMID: 31370779; PubMed Central PMCID: PMCPMC6676516.
    OpenUrlCrossRefPubMed
  67. 67.↵
    Habeebuddin M, Karnati RK, Shiroorkar PN, Nagaraja S, Asdaq SMB, Khalid Anwer M, et al. Topical Probiotics: More Than a Skin Deep. Pharmaceutics. 2022;14(3). Epub 2022/03/27. doi: 10.3390/pharmaceutics14030557. PubMed PMID: 35335933; PubMed Central PMCID: PMCPMC8955881.
    OpenUrlCrossRefPubMed
  68. 68.↵
    Damiani G, Bragazzi NL, McCormick TS, Pigatto PDM, Leone S, Pacifico A, et al. Gut microbiota and nutrient interactions with skin in psoriasis: A comprehensive review of animal and human studies. World journal of clinical cases. 2020;8(6):1002–12. Epub 2020/04/08. doi: 10.12998/wjcc.v8.i6.1002. PubMed PMID: 32258071; PubMed Central PMCID: PMCPMC7103976.
    OpenUrlCrossRefPubMed
  69. 69.↵
    Le ST, Toussi A, Maverakis N, Marusina AI, Barton VR, Merleev AA, et al. The cutaneous and intestinal microbiome in psoriatic disease. Clinical immunology (Orlando, Fla). 2020;218:108537. Epub 2020/07/18. doi: 10.1016/j.clim.2020.108537. PubMed PMID: 32679247.
    OpenUrlCrossRefPubMed
  70. 70.↵
    Sinha S, Lin G, Ferenczi K. The skin microbiome and the gut-skin axis. Clinics in dermatology. 2021;39(5):829–39. Epub 2021/11/18. doi: 10.1016/j.clindermatol.2021.08.021. PubMed PMID: 34785010.
    OpenUrlCrossRefPubMed
  71. 71.↵
    Todberg T, Kaiser H, Zachariae C, Egeberg A, Halling AS, Skov L. Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review. Acta dermato-venereologica. 2021;101(7):adv00512. Epub 2021/07/16. doi: 10.2340/00015555-3882. PubMed PMID: 34263334.
    OpenUrlCrossRefPubMed
  72. 72.↵
    Carmona-Cruz S, Orozco-Covarrubias L, Sáez-de-Ocariz M. The Human Skin Microbiome in Selected Cutaneous Diseases. Frontiers in cellular and infection microbiology. 2022;12:834135. Epub 2022/03/25. doi: 10.3389/fcimb.2022.834135. PubMed PMID: 35321316; PubMed Central PMCID: PMCPMC8936186.
    OpenUrlCrossRefPubMed
  73. 73.↵
    Eppinga H, Sperna Weiland CJ, Thio HB, van der Woude CJ, Nijsten TE, Peppelenbosch MP, et al. Similar Depletion of Protective Faecalibacterium prausnitzii in Psoriasis and Inflammatory Bowel Disease, but not in Hidradenitis Suppurativa. Journal of Crohn’s & colitis. 2016;10(9):1067–75. Epub 2016/03/14. doi: 10.1093/ecco-jcc/jjw070. PubMed PMID: 26971052.
    OpenUrlCrossRefPubMed
  74. 74.↵
    Zorba M, Melidou A, Patsatsi A, Ioannou E, Kolokotronis A. The possible role of oral microbiome in autoimmunity. International journal of women’s dermatology. 2020;6(5):357–64. Epub 2021/04/27. doi: 10.1016/j.ijwd.2020.07.011. PubMed PMID: 33898698; PubMed Central PMCID: PMCPMC8060669.
    OpenUrlCrossRefPubMed
  75. 75.↵
    Curtis MA, Diaz PI, Van Dyke TE. The role of the microbiota in periodontal disease. Periodontology 2000. 2020;83(1):14–25. Epub 2020/05/10. doi: 10.1111/prd.12296. PubMed PMID: 32385883.
    OpenUrlCrossRefPubMed
  76. 76.
    Costalonga M, Herzberg MC. The oral microbiome and the immunobiology of periodontal disease and caries. Immunology letters. 2014;162(2 Pt A):22–38. Epub 2014/12/03. doi: 10.1016/j.imlet.2014.08.017. PubMed PMID: 25447398; PubMed Central PMCID: PMCPMC4346134.
    OpenUrlCrossRefPubMed
  77. 77.↵
    Vieira Colombo AP, Magalhães CB, Hartenbach FA, Martins do Souto R, Maciel da Silva-Boghossian C. Periodontal-disease-associated biofilm: A reservoir for pathogens of medical importance. Microbial pathogenesis. 2016;94:27–34. Epub 2015/09/30. doi: 10.1016/j.micpath.2015.09.009. PubMed PMID: 26416306.
    OpenUrlCrossRefPubMed
  78. 78.↵
    Weinstabl A, Hoff-Lesch S, Merk HF, von Felbert V. Prospective randomized study on the efficacy of blue light in the treatment of psoriasis vulgaris. Dermatology (Basel, Switzerland). 2011;223(3):251–9. Epub 2011/11/23. doi: 10.1159/000333364. PubMed PMID: 22105015.
    OpenUrlCrossRefPubMed
  79. 79.↵
    Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta dermato-venereologica. 2012;92(5):497–501. Epub 2011/11/22. doi: 10.2340/00015555-1265. PubMed PMID: 22102095.
    OpenUrlCrossRefPubMed
  80. 80.
    1. Benzon HT,
    2. Raja SN,
    3. Liu SS,
    4. Fishman SM,
    5. Cohen SP, editors
    Lazaridou A, Elbaridi N, Edwards RR, Berde CB. Chapter 5 - Pain Assessment. In: Benzon HT, Raja SN, Liu SS, Fishman SM, Cohen SP, editors. Essentials of Pain Medicine (Fourth Edition): Elsevier; 2018. p. 39–46.e1.
  81. 81.↵
    Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta dermato-venereologica. 2012;92(5):502–7. Epub 2011/12/16. doi: 10.2340/00015555-1246. PubMed PMID: 22170091.
    OpenUrlCrossRefPubMedWeb of Science
  82. 82.↵
    Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–14. Epub 2012/06/16. doi: 10.1038/nature11234. PubMed PMID: 22699609; PubMed Central PMCID: PMCPMC3564958.
    OpenUrlCrossRefPubMedWeb of Science
  83. 83.↵
    Lin H, Peddada SD. Analysis of microbial compositions: a review of normalization and differential abundance analysis. NPJ biofilms and microbiomes. 2020;6(1):60. Epub 2020/12/04. doi: 10.1038/s41522-020-00160-w. PubMed PMID: 33268781; PubMed Central PMCID: PMCPMC7710733.
    OpenUrlCrossRefPubMed
Back to top
Posted March 09, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: Protocol for a Randomized Controlled Trial (CanPatch)
Pim Sermsaksasithorn, Pravit Asawanonda, Phanupong Phutrakool, Thunnicha Ondee, Pajaree Chariyavilaskul, Sunchai Payungporn, Krit Pongpirul, Nattiya Hirankarn
medRxiv 2023.03.08.23286926; doi: https://doi.org/10.1101/2023.03.08.23286926
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area